ArticleBlood cancer journal2016
Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Guideline
- The critical role of ferroptosis in virus-associated hematologic malignancies and its potential value in antiviral-antitumor therapy.Virulence · 2025Review
- HTLV-1 and ATLL: Epidemiology, Oncogenesis, and Opportunities for Community-Informed Research in the United States.Viruses · 2025Review
- Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges.Viruses · 2025Review
- Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin.International journal of molecular sciences · 2024Review
- Article
- Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions.Current treatment options in oncology · 2023Review
- GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.Bone marrow transplantation · 2021Article
- Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.International journal of molecular sciences · 2020Review
- The Antihelminthic Drug, Mebendazole, Induces Apoptosis in Adult T-Cell Leukemia/Lymphoma Cancer Cells:International journal of hematology-oncology and stem cell research · 2020Article
- Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.Retrovirology · 2020Article
- Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1-infected cells.Blood advances · 2020Article
- Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.Current hematologic malignancy reports · 2018Review
- An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia.The Journal of biological chemistry · 2018Article
- A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies.Advances in therapy · 2018Review
- Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma.Frontiers in microbiology · 2018Review
- Adult T-Cell Leukemia/Lymphoma.Journal of oncology practice · 2017Review
- Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies.Cancer investigation · 2017Article
- Human T-cell leukemia virus-associated malignancy.Current opinion in virology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
L RatnerDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
D RauchDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
H AbelDepartment of Genetics, Washington University School of Medicine, St Louis, MO, USA.
B CarusoViral Immunology Section, Neuroimmunology and Neurovirology Division, NINDS, NIH, Bethesda, MD, USA.
A NoyLymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
S K BartaDivision of Hematology-Oncology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
S ParekhDivision of Hematology-Oncology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
J C RamosDivision of Hematology-Oncology, Department of Medicine, University of Miami School of Medicine, Miami, FL, USA.
R AmbinderDivision of Hematologic Malignancies, Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
A PhillipsDivision of Hematology-Oncology, Department of Medicine, Columbia University Medical Center, New York, NY, USA.
J HardingDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
H H BaydounDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
X ChengDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
S JacobsonViral Immunology Section, Neuroimmunology and Neurovirology Division, NINDS, NIH, Bethesda, MD, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MRole of Inflammation in Tax-mediated TumorigenesisP01CA100730 · NCI · WASHINGTON UNIVERSITY · PI Malachi Griffith · 2003 to 2026
$44.8MTargeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI TODD A FEHNIGER · 2013 to 2026
$31.6MWU-MDACC Inter-Institutional Molecular Imaging CenterP50CA094056 · NCI · WASHINGTON UNIVERSITY · PI KOPAN, RAPHAEL · 2002 to 2016
$26.3MTranslational studies of human viruses and chronic neurologic diseaseZIANS003040 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI JACOBSON, STEVEN · 2009 to 2025
$10.1MPROLIFERATIVE EFFECTS OF HTLV1R01CA063417 · NCI · WASHINGTON UNIVERSITY · PI RATNER, LEE · 1995 to 2017
$3.7MNCI NIH HHS CA10073NCI NIH HHS CA 63417NCI NIH HHS CA94056NCI NIH HHS P01 CA100730NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA094056NCI NIH HHS P50 CA171963NCI NIH HHS R01 CA063417
Abstract
PubMed holds no abstract for this paper.
Indexed as
Human T-lymphotropic virus 1Antineoplastic Combined Chemotherapy ProtocolsBortezomibCyclophosphamideDoxorubicinEtoposideHTLV-I InfectionsHumansLeukemia-Lymphoma, Adult T-CellPrednisoneRaltegravir PotassiumTreatment OutcomeVincristineBortezomibCyclophosphamideDoxorubicinEtoposidePrednisoneRaltegravir PotassiumVincristine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.